STOCK TITAN

Vera Therapeutics (VERA) Financials

VERA NASDAQ
Trailing 12 months to September 30, 2026
Net Income -$415.3M n/m YoY
EPS (Diluted) -$5.90 n/m YoY
Free Cash Flow -$376.0M n/m YoY
Operating Cash Flow -$375.9M n/m YoY
Market Cap $1.8B as of Nov 20, 2026
Price / Sales n/m no full year of revenue reported yet
Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to September 30, 2026
Price / Book 5.5x on $333.2M equity, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 20, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2026, filed Nov 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the VERA SEC filings page.

This page shows Vera Therapeutics, Inc. (VERA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI VERA FY2025

Vera is a development-stage business where escalating research spending, not revenue, drives losses and cash needs.

In FY2025, the net loss was $299.6M while operating cash flow was -$241.1M, so accounting losses translated into nearly comparable cash use. Free cash flow was -$241.7M, reinforcing that capital spending did not materially change the cash requirement.

R&D reached $215.3M in FY2025 from $126.2M in FY2024, showing development spending is still accelerating. SG&A also reached $100.2M, so expansion is not confined to research; with revenue unreported, the statements describe a development-led cost structure rather than a commercial revenue engine.

Liabilities were 17.7% of assets in FY2025, while debt-to-equity was 0.1x, indicating a predominantly equity-funded balance sheet. Reported liquidity equaled 35.6 months of annual outflow, even as current liabilities rose 110.7%, showing that near-term obligations are becoming more consequential.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Financial health score not available

We do not publish a peer-relative financial health score for Vera Therapeutics, Inc., because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.

Piotroski F-Score Partial
1/7

Vera Therapeutics, Inc. passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality No Cash Backing
N/A

Vera Therapeutics, Inc. reported a net loss of $299.6M while operations used $241.1M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk
N/A

Vera Therapeutics, Inc. reported an operating loss of $315.5M against $7.5M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$10.3M
YoYn/m

Vera Therapeutics, Inc. generated $10.3M in revenue in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.

EBITDA
-$94.9M
YoYn/m
QoQn/m
5Y CAGRn/m

Vera Therapeutics, Inc.'s EBITDA was -$94.9M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Net Income
-$93.7M
YoYn/m
QoQn/m
5Y CAGRn/m

Vera Therapeutics, Inc. reported a net loss of $93.7M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)
-$1.30
YoYn/m
QoQn/m
5Y CAGRn/m

Vera Therapeutics, Inc. earned -$1.30 per diluted share (EPS) in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Balance Sheet

Free Cash Flow
-$99.2M
YoYn/m
QoQn/m
5Y CAGRn/m

Vera Therapeutics, Inc. recorded an outflow of $99.2M in free cash flow in Q3 2026, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Debt
$55.3M
YoY-4.2%
QoQ+13.2%
5Y CAGR-8.5%

Vera Therapeutics, Inc. held $55.3M in cash against $75.4M in long-term debt as of Q3 2026.

Shares Outstanding
72M
YoY+13.1%
QoQ+0.3%
5Y CAGR+27.7%

Vera Therapeutics, Inc. had 72M shares outstanding in Q3 2026. This represents an increase of 13.1% from the same quarter a year earlier. Against the prior quarter it is up 0.3%.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Gross Margin
67.9%

Vera Therapeutics, Inc.'s gross margin was 67.9% in Q3 2026, indicating the percentage of revenue retained after direct costs.

Return on Equity
-28.1%
YoY-8.0pp
QoQ-1.3pp
5Y change-19.2pp

Vera Therapeutics, Inc.'s quarterly ROE was -28.1% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is down 8.0 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.3 percentage points.

Operating Margin

Not shown for Q3 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

Not shown for Q3 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Capital Allocation

R&D Spending
$41.3M
YoY-27.0%
QoQ-31.3%
5Y CAGR+63.2%

Vera Therapeutics, Inc. invested $41.3M in research and development in Q3 2026. This represents a decrease of 27.0% from the same quarter a year earlier. Against the prior quarter it is down 31.3%.

Capital Expenditures
$0
YoY-100.0%
QoQn/m
5Y CAGRn/m

Vera Therapeutics, Inc. reported no capital expenditure in Q3 2026. This represents a decrease of 100.0% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Share Buybacks

Not reported for Q3 2026.

VERA Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

VERA quarterly income statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Revenue$10.3Mn/mN/AN/AN/A$0N/AN/AN/A
Cost of Revenue$3.3Mn/mN/AN/AN/A$0N/AN/AN/A
Gross Profit$7.0Mn/mN/AN/AN/A$0N/AN/AN/A
R&D Expenses$41.3M-27.0%$60.1M+3.2%$86.0M+108.4%$59.3M+77.9%$56.5M+40.1%$58.2M+98.5%$41.3M+77.9%$33.3M+60.4%
SG&A Expenses$61.4M+123.7%$52.4M+138.8%$39.1M+145.8%$34.9M+124.2%$27.5M+189.4%$21.9M+173.2%$15.9M+101.2%$15.6M+149.4%
Operating Income-$95.7Mn/m-$112.5Mn/m-$125.1Mn/m-$94.2Mn/m-$83.9Mn/m-$80.1Mn/m-$57.2Mn/m-$48.9Mn/m
EBITDA-$94.9Mn/m-$112.4Mn/m-$125.0Mn/m-$94.1Mn/m-$83.8Mn/m-$80.0Mn/m-$57.1Mn/m-$48.9Mn/m
Interest Expense$1.9M-4.4%$1.8M-1.4%$1.8M+1.7%$1.9M+1.8%$2.0M+1.2%$1.9M-2.0%$1.8M-6.0%$1.9M+77.4%
Net Income-$93.7Mn/m-$109.5Mn/m-$121.0Mn/m-$91.1Mn/m-$80.3Mn/m-$76.5Mn/m-$51.7Mn/m-$43.4Mn/m
EPS (Basic)-$1.30n/m-$1.52n/m-$1.69n/m-$1.39n/m-$1.26n/m-$1.20n/m-$0.81n/m-$0.72n/m
EPS (Diluted)-$1.30n/m-$1.52n/m-$1.69n/m-$1.39n/m-$1.26n/m-$1.20n/m-$0.81n/m-$0.72n/m
Diluted Shares (Avg)72M+13.0%72M+12.6%71M+12.3%N/A64M+16.3%64M+16.6%64M+24.9%N/A

Not reported in any period shown, so not listed: Income Tax.

VERA Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

VERA quarterly balance sheet
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-QQ3'2510-QQ2'2510-QQ1'25FilingQ4'2410-K
Total Assets$465.8M-10.0%$533.0M-7.9%$621.7M+1.9%$734.7M+12.1%$517.5M+40.4%$578.5M+45.6%$610.2M+45.5%$655.7M+273.5%
Current Assets$441.3M-13.7%$527.5M-7.7%$615.8M+1.6%$728.9M+11.9%$511.3M+40.4%$571.4M+44.7%$606.1M+45.6%$651.2M+278.6%
Cash & Equivalents$55.3M-4.2%$48.9M-0.5%$114.4M+107.6%$354.7M+282.9%$57.8M+112.0%$49.1M+95.8%$55.1M-20.3%$92.6M+102.8%
Short-Term Investments$328.7M-25.2%$450.3M-11.3%$482.4M-9.8%$359.9M-34.4%$439.6M+34.8%$507.7M+41.3%$534.7M+59.8%$548.2M+376.6%
Inventory$7.1MN/AN/A$0N/AN/AN/AN/A
Accounts Receivable$12.0MN/AN/A$0N/AN/AN/AN/A
Long-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0-100.0%
Total Liabilities$132.6M+11.8%$125.2M+13.6%$122.0M+62.4%$130.2M+65.8%$118.6M+49.2%$110.3M+58.8%$75.2M+14.2%$78.5M+6.3%
Current Liabilities$55.8M+33.2%$48.3M+44.0%$45.1M+106.2%$53.5M+110.7%$41.9M+58.3%$33.6M+82.2%$21.9M+50.5%$25.4M+13.8%
Non-Current Liabilities$76.8M+0.1%$76.9M+0.3%$76.9M+44.3%$76.8M+44.4%$76.7M+44.7%$76.7M+50.4%$53.3M+3.9%$53.2M+3.1%
Long-Term Debt$75.4M+1.1%$75.2M+1.0%$75.0M+47.4%$74.8M+47.6%$74.6M+47.9%$74.5M+48.1%$50.9M+1.7%$50.7M+1.6%
Total Equity$333.2M-16.5%$407.8M-12.9%$499.7M-6.6%$604.5M+4.7%$398.9M+38.0%$468.3M+42.8%$535.0M+51.3%$577.2M+467.6%
Retained Earnings-$1.1Bn/m-$991.4Mn/m-$881.9Mn/m-$760.9Mn/m-$669.8Mn/m-$589.5Mn/m-$512.9Mn/m-$461.3Mn/m

Not reported in any period shown, so not listed: Goodwill.

VERA Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

VERA quarterly cash flow statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Cash Flow-$99.2Mn/m-$100.3Mn/m-$106.5Mn/m-$70.0Mn/m-$61.9Mn/m-$54.8Mn/m-$54.4Mn/m-$39.2Mn/m
Depreciation & Amortization$823K+538.0%$132K+10.9%$140K+64.7%$135K+145.5%$129K+437.5%$119K+693.3%$85K+672.7%$55K+1275.0%
Stock-Based Compensation$15.7M+61.4%$15.9M+67.5%$13.2M+70.6%N/A$9.7M+74.4%$9.5M+94.4%$7.7M+87.8%N/A
Capital Expenditures$0-100.0%$0-100.0%$23K-87.7%$102K-84.2%$133K-44.1%$208K+133.7%$187Kn/m$645K+923.8%
Free Cash Flow-$99.2Mn/m-$100.3Mn/m-$106.5Mn/m-$70.1Mn/m-$62.0Mn/m-$55.0Mn/m-$54.6Mn/m-$39.8Mn/m
Investing Cash Flow$101.9M+46.1%$32.9M+15.1%-$137.8M-999.8%$80.7Mn/m$69.8M+82.1%$28.5Mn/m$15.3Mn/m-$221.4M-1293.1%
Financing Cash Flow$3.7M+365.7%$1.9M-90.5%$3.9M+157.1%$286.3M-12.2%$797K+7.8%$20.3M+489.9%$1.5M-99.4%$326.0M+1212.9%
Share BuybacksN/AN/AN/A$0n/mN/AN/AN/A$0n/m

Not reported in any period shown, so not listed: Dividends Paid.

VERA Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

VERA quarterly financial ratios
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Gross Margin67.9%N/AN/AN/AN/AN/AN/AN/A
Operating Margin-931.2%N/AN/AN/AN/AN/AN/AN/A
Net Margin-911.9%N/AN/AN/AN/AN/AN/AN/A
Return on Equity-28.1%-8.0pp-26.9%-10.5pp-24.2%-14.6pp-15.1%-7.5pp-20.1%-4.0pp-16.3%-6.1pp-9.7%-1.6pp-7.5%+17.7pp
Return on Assets-20.1%-4.6pp-20.5%-7.3pp-19.5%-11.0pp-12.4%-5.8pp-15.5%-2.9pp-13.2%-4.8pp-8.5%-1.7pp-6.6%+8.0pp
Current Ratio7.91-4.3x10.92-6.1x13.64-14.0x13.64-12.0x12.21-1.6x17.03-4.4x27.68-0.9x25.67+18.0x
Debt-to-Equity0.230.0x0.180.0x0.15+0.1x0.120.0x0.190.0x0.160.0x0.100.0x0.09-0.4x
Liabilities-to-Equity0.40+0.1x0.31+0.1x0.24+0.1x0.22+0.1x0.300.0x0.240.0x0.140.0x0.14-0.6x
Asset Turnover0.020.0xN/AN/AN/A0.00N/AN/AN/A
FCF Margin-965.0%N/AN/AN/AN/AN/AN/AN/A

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Vera Therapeutics, Inc. VERA FY2025 N/A -$299.6M N/A $1.8B —
Immunome, Inc. IMNM FY2025 $6.9M -$212.4M N/A $1.9B 50/100
Aurinia Pharmaceuticals Inc AUPH FY2025 $283.1M $287.2M N/A $2.0B 67/100
Biohaven Ltd. BHVN FY2025 N/A -$738.8M N/A $1.9B —
Septerna, Inc. SEPN FY2025 $46.0M -$48.9M N/A $1.8B 46/100
Celldex Therapeutics, Inc CLDX FY2025 $1.5M -$258.8M N/A $2.2B 56/100

Frequently Asked Questions

No, Vera Therapeutics, Inc. (VERA) reported a net loss of $415.3M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net loss of $299.6M.

Vera Therapeutics, Inc. (VERA) reported diluted earnings per share of -$4.66 for fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Vera Therapeutics, Inc. (VERA) had EBITDA of -$315.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

As of fiscal year 2025, Vera Therapeutics, Inc. (VERA) had $354.7M in cash and equivalents against $74.8M in long-term debt.

Vera Therapeutics, Inc. (VERA) has a return on equity of -49.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Vera Therapeutics, Inc. (VERA) recorded an outflow of $241.7M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Vera Therapeutics, Inc. (VERA) recorded an outflow of $241.1M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

Vera Therapeutics, Inc. (VERA) had $734.7M in total assets as of fiscal year 2025, including both current and long-term assets.

Vera Therapeutics, Inc. (VERA) invested $630K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Vera Therapeutics, Inc. (VERA) invested $215.3M in research and development during fiscal year 2025.

Vera Therapeutics, Inc. (VERA) had 71M shares outstanding as of fiscal year 2025.

Vera Therapeutics, Inc. (VERA) had a current ratio of 13.64 as of fiscal year 2025, which is generally considered healthy.

Vera Therapeutics, Inc. (VERA) had a debt-to-equity ratio of 0.12 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.

Vera Therapeutics, Inc. (VERA) had a liabilities-to-equity ratio of 0.22 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.

Vera Therapeutics, Inc. (VERA) had a return on assets of -40.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Vera Therapeutics, Inc. (VERA) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $1.8B as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Vera Therapeutics, Inc. (VERA) has no price-to-sales ratio at the moment: no full year of revenue reported yet. The market capitalization is $1.8B as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2025, Vera Therapeutics, Inc. (VERA) held $714.6M in cash, cash equivalents and investments, and reported an operating cash outflow of $241.1M over that year. Dividing the one by the other, the reported balance equals about 36 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Vera Therapeutics, Inc. (VERA) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Vera Therapeutics, Inc. (VERA) reported a net loss of $299.6M while operations used $241.1M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Vera Therapeutics, Inc. (VERA) reported an operating loss of $315.5M against $7.5M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

Back to top